{"id":6321,"date":"2023-09-05T21:14:34","date_gmt":"2023-09-05T15:44:34","guid":{"rendered":"https:\/\/farratanews.online\/new-ai-generated-covid-drug-enters-phase-i-clinical-trials-effective-against-all-variants\/"},"modified":"2023-09-05T21:14:34","modified_gmt":"2023-09-05T15:44:34","slug":"new-ai-generated-covid-drug-enters-phase-i-clinical-trials-effective-against-all-variants","status":"publish","type":"post","link":"https:\/\/farratanews.online\/new-ai-generated-covid-drug-enters-phase-i-clinical-trials-effective-against-all-variants\/","title":{"rendered":"New AI-generated COVID drug enters Phase I clinical trials: \u2018Effective against all variants\u2019"},"content":{"rendered":"
[ad_1]
\n<\/p>\n
Artificial intelligence<\/u> is increasingly moving into the health care arena and helping to streamline medical processes \u2014 including the creation of new drugs.<\/p>\n
Insilico Medicine, an AI-driven biotech company based in Hong Kong and in New York City, recently announced that its new AI-designed drug for COVID-19 has entered Phase I clinical trials.<\/p>\n
This oral drug is a treatment, not a vaccine. If approved, it would become the first-ever alternative to Paxlovid, noted Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine.<\/p>\n
WHAT IS ARTIFICIAL INTELLIGENCE?<\/u><\/strong><\/p>\n “Generative AI is transforming every area of human development,” said Zhavoronkov in a press release announcing the new discovery.\u00a0<\/p>\n “We\u2019re extremely happy to announce that our second small molecule therapeutic \u2014 generated using generative AI \u2014 is now entering human clinical trials.”\u00a0<\/p>\n